- Fatouros, D.G., Karpf, D.M., Nielsen, F.S., & Mullertz, A. (2007). Clinical studies with oral lipid based formulations of poorly soluble compounds. *Therapeutics and Clinical Risk Management*, 3(4), 591–604.
- Fernández-Urrusuno, R.1., Calvo, P., Remuñán-López, C., Vila-Jato, J.L., & Alonso, M.J. (1999). Enhancement of nasal absorption of insulin using chitosan nanoparticles. *Pharm. Res*, 16(10), 1576–1581.
- Finkel, R., Clark, M., & Cubeddu, L. (2009). *Pharmacology*. Philadelphia: Lippincott Williams & Wilkins.
- Fonseca, V. (2006). The role of basal insulin therapy in patients with type 2 diabetes mellitus. *Insulin*, 1(2), 51-60.
- Foss, A.C., Goto, T., Morishita, M., & Peppas, N.A. (2004). Development of acrylic-based copolymers for oral insulin delivery. *Eur.J.Pharm.Biopharm*, 57(2), 163-169.
- Freeman, H., & Kim, Y. (1978). Digestion and Absorption of Protein. *Annu. Rev. Med.*, 29(1), 99-116.
- Gan, Q., & Wang, T. (2007). Chitosan nanoparticle as protein delivery carrier—systematic examination of fabrication conditions for efficient loading and release. *Colloids Surf. B Biointerfaces*, 59(1), 24-34.
- Gao, Q., & Wan, A. (2006). Effects of molecular weight, degree of acetylation and ionic strength on surface tension of chitosan in dilute solution. *Carbohydrate Polymers*, 64(1), 29-36.
- Gavhane, Y.N., & Yadav, A.V. (2012). Loss of orally administered drugs in GI tract. *Saudi Pharmaceutical Journal : SPJ*, 20(4), 331–344.
- Ghosh, T., & Pfister, W. (2005). *Drug delivery to the oral cavity*. Boca Raton: Taylor & Francis.